BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

481 related articles for article (PubMed ID: 28650002)

  • 1. Cabozantinib use in renal cell carcinoma.
    Neuwelt AJ; Mathur S; Johnson AT; Kessler ER; Bowles DW
    Drugs Today (Barc); 2017 May; 53(5):299-307. PubMed ID: 28650002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma.
    Schmidinger M; Danesi R
    Oncologist; 2018 Mar; 23(3):306-315. PubMed ID: 29146618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In brief: Cabozantinib (Cabometyx) for advanced renal cell carcinoma.
    Med Lett Drugs Ther; 2016 Jul; 58(1499):e97. PubMed ID: 27403787
    [No Abstract]   [Full Text] [Related]  

  • 4. Cabozantinib for the treatment of renal cell carcinoma.
    Escudier B; Lougheed JC; Albiges L
    Expert Opin Pharmacother; 2016 Dec; 17(18):2499-2504. PubMed ID: 27835047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cabozantinib: A Review in Advanced Renal Cell Carcinoma.
    Al-Salama ZT; Keating GM
    Drugs; 2016 Dec; 76(18):1771-1778. PubMed ID: 27909994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis.
    Campbell MT; Bilen MA; Shah AY; Lemke E; Jonasch E; Venkatesan AM; Altinmakas E; Duran C; Msaouel P; Tannir NM
    Eur J Cancer; 2018 Nov; 104():188-194. PubMed ID: 30380460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of Prior Tyrosine Kinase Inhibitor on Survival for Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab or Cabozantinib: Data from a Literature-based Meta-analysis.
    Roviello G; Generali D
    Eur Urol; 2017 Dec; 72(6):1027-1028. PubMed ID: 28760645
    [No Abstract]   [Full Text] [Related]  

  • 8. Cabozantinib for the treatment of kidney cancer.
    Abdelaziz A; Vaishampayan U
    Expert Rev Anticancer Ther; 2017 Jul; 17(7):577-584. PubMed ID: 28633552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma.
    Donskov F; Motzer RJ; Voog E; Hovey E; Grüllich C; Nott LM; Cuff K; Gil T; Jensen NV; Chevreau C; Negrier S; Depenbusch R; Bergmann L; Cornelio I; Champsaur A; Escudier B; Pal S; Powles T; Choueiri TK
    Eur J Cancer; 2020 Feb; 126():1-10. PubMed ID: 31887537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NICE guidance on cabozantinib for previously treated advanced renal cell carcinoma.
    Elsada A; Adler AI
    Lancet Oncol; 2017 Sep; 18(9):1153-1154. PubMed ID: 28800862
    [No Abstract]   [Full Text] [Related]  

  • 11. Cabozantinib Approved for Renal Cell Carcinoma.
    Cancer Discov; 2016 Jun; 6(6):OF3. PubMed ID: 27150533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cabozantinib improves clinical outcomes in renal cancer.
    Das M
    Lancet Oncol; 2017 Jan; 18(1):e2. PubMed ID: 27890466
    [No Abstract]   [Full Text] [Related]  

  • 13. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.
    Choueiri TK; Escudier B; Powles T; Mainwaring PN; Rini BI; Donskov F; Hammers H; Hutson TE; Lee JL; Peltola K; Roth BJ; Bjarnason GA; Géczi L; Keam B; Maroto P; Heng DY; Schmidinger M; Kantoff PW; Borgman-Hagey A; Hessel C; Scheffold C; Schwab GM; Tannir NM; Motzer RJ;
    N Engl J Med; 2015 Nov; 373(19):1814-23. PubMed ID: 26406150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cabozantinib for Renal Cell Carcinoma: Current and Future Paradigms.
    Abdelaziz A; Vaishampayan U
    Curr Treat Options Oncol; 2017 Mar; 18(3):18. PubMed ID: 28286925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cabozantinib approved for first-line treatment of advanced renal cell carcinoma.
    Clin Adv Hematol Oncol; 2018 Feb; 16(2):96. PubMed ID: 29741507
    [No Abstract]   [Full Text] [Related]  

  • 16. Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma.
    McGregor BA; Lalani AA; Xie W; Steinharter JA; E Bakouny Z; Martini DJ; Fleischer JH; Abou-Alaiwi S; Nassar A; Nuzzo PV; Kaymakcalan MD; Braun DA; Wei XX; Harshman LC; Bilen MA; Choueiri TK
    Eur J Cancer; 2020 Aug; 135():203-210. PubMed ID: 32599410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of advanced renal cell carcinoma patients with cabozantinib, an oral multityrosine kinase inhibitor of MET, AXL and VEGF receptors.
    Desai A; Small EJ
    Future Oncol; 2019 Jul; 15(20):2337-2348. PubMed ID: 31184937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma.
    Tannir NM; Schwab G; Grünwald V
    Curr Oncol Rep; 2017 Feb; 19(2):14. PubMed ID: 28247252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy of cabozantinib in two pediatric patients with recurrent renal cell carcinoma.
    Wedekind MF; Ranalli M; Shah N
    Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28417541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).
    Bowles DW; Kessler ER; Jimeno A
    Drugs Today (Barc); 2011 Nov; 47(11):857-68. PubMed ID: 22146228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.